Original Research

DOI: 10.4244/EIJ-D-24-00763

Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: five-year results of the randomised, non-inferiority SORT OUT VIII trial

Nicolaj Brejnholt Støttrup1,2, MD, PhD; Evald Høj Christiansen1,2, MD, PhD; Bent Raungaard3, MD, PhD; Johnny Kahlert4, PhD; Christian Juhl Terkelsen1,2, MD, DMSc; Steen Dalby Kristensen1,2, MD, DMSc; Troels Thim1,2, MD, PhD; Lars Jakobsen1, MD, PhD; Rebekka Vibjerg Jensen1,2, MD, PhD; Ashkan Eftekhari3, MD, PhD; Phillip Freeman3, MD; Svend Eggert Jensen3, MD, PhD; Karsten Tange Veien1,5, MD; Lisette Okkels Jensen5, MD, DMSc; Michael Maeng1,2, MD, PhD; for the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT)

Abstract

Background: Long-term outcomes following implantation of drug-eluting coronary stents are necessary to determine safety and efficacy.

Aims: We aimed to report the 5-year outcomes of the SYNERGY thin-strut biodegradable-polymer everolimus-eluting platinum-chromium stent (EES) versus the BioMatrix NeoFlex biodegradable-polymer biolimus-eluting stainless-steel stent (BES).

Methods: This randomised, multicentre, all-comer, non-inferiority trial was undertaken at three sites in Western Denmark. Patients with a clinical indication for percutaneous coronary intervention were eligible for inclusion. Patients were randomly assigned (1:1) to either EES or BES. Outcomes included target lesion failure (TLF: cardiac death, myocardial infarction not clearly attributable to a non-target lesion, or target lesion revascularisation), all myocardial infarctions, and very late stent thrombosis at 5-year follow-up.

Results: We included 2,764 patients and randomly assigned 1,385 patients to treatment with EES and 1,379 patients to treatment with BES. TLF occurred in 150 patients (10.8%) assigned to the EES and in 165 (12.0%) assigned to the BES (rate ratio [RR] 0.88, 95% confidence interval [CI]: 0.71-1.10). The incidence of myocardial infarction was lower in the EES group (EES: n=85 [6.1%], BES: n=116 [8.4%]; RR 0.71, 95% CI: 0.54-0.95), while very late stent thrombosis was rare for both stent types (EES: n=12 [0.9%], BES: n=9 [0.7%]; RR 1.32, 95% CI: 0.56-3.14).

Conclusions: At 5-year follow-up, TLF was comparable for EES and BES. The incidence of myocardial infarction, however, was lower in patients randomised to EES versus BES implantation.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 11
Jun 2, 2025
Volume 21 Number 11
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV17I5A62 Aug 6, 2021
DAPT duration in acute coronary syndrome: is stent type an issue?
Gilard M and Didier R
free

10.4244/EIJV9I3A55 Jul 26, 2013
Long-term comparison of everolimus-eluting and biolimus-eluting stents
Puricel S et al
free
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
26

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved